Reduction in Neuroleptic-Induced Movement Disorders After a Switch to Quetiapine in Patients With Schizophrenia
The DOI matches its Crossref record.
Abstract
BACKGROUND: Persistent neuroleptic-induced movement disorders limit effective pharmacological management of psychotic disorders. Although antipsychotic switching is a common strategy for managing extrapyramidal side effects (EPSs), there is insufficient empirical support to guide the clinician. We designed the present study to examine whether patients with preexisting EPS switched to quetiapine would show greater reduction in EPS compared with control patients. METHODS: Twenty-two patients with schizophrenia meeting clinical criteria for tardive dyskinesia or coexisting parkinsonism were randomized either to switch from their current antipsychotic to quetiapine (n = 13) or to remain on their current treatment (n = 9). A battery of standard clinical assessments for EPS along with electromechanical instrumental measures was administered before randomization and again 1 and 3 months postrandomization. RESULTS: We observed significant reduction in parkinsonism (P < 0.001) and akathisia (P = 0.02) based on clinical assessments and dyskinesia (P < 0.05) based on instrumental assessment for the quetiapine group. Subjects remaining on current treatment exhibited an increase in rigidity (P < 0.05) based on instrumental measures. CONCLUSIONS: These findings support the switching to quetiapine in the management of preexisting neuroleptic-induced extrapyramidal side effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Management of common adverse effects of antipsychotic medications
Stroup, T. S., & Gray, N. (2018) · World Psychiatry · doi:10.1002/wps.20567 · Cited by 572
Hasan, A., Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Thibaut, F., Möller, H.-J., & WFSBP Task force on Treatment Guidelines for Schizophrenia (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2012.739708 · Cited by 416
Quetiapine versus other atypical antipsychotics for schizophrenia
Komossa, K., Rummel-Kluge, C., Schmid, F., Hunger, H., Schwarz, S., Srisurapanont, M., Kissling, W., & Leucht, S. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006625.pub2 · Cited by 260
Cerovecki, A., Musil, R., Klimke, A., Seemüller, F., Haen, E., Schennach, R., Kühn, K.-U., Volz, H.-P., & Riedel, M. (2013) · CNS Drugs · doi:10.1007/s40263-013-0079-5 · Cited by 112
Cohen, D., & Recalt, A. (2019) · Psychotherapy and Psychosomatics · doi:10.1159/000496733 · Cited by 28
Metadata
- Authors
- Cortese, L., Caligiuri, M. P., Williams, R., Schieldrop, P., Manchanda, R., Malla, A., & Harricharan, R.
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2008-02
- Volume
- 28
- Issue
- 1
- Pages
- 69-73
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W2008291750
- Cited by
- 47
- References
- 0
- FWCI
- 4.18
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Reduction in Neuroleptic-Induced Movement Disorders After a Switch to Quetiapine in Patients With Schizophrenia. https://app.cochat.ai/papers/10.1097/jcp.0b013e318160864f
- The paper
- Cortese, L., Caligiuri, M. P., Williams, R., Schieldrop, P., Manchanda, R., Malla, A., & Harricharan, R. (2008). Reduction in Neuroleptic-Induced Movement Disorders After a Switch to Quetiapine in Patients With Schizophrenia. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/jcp.0b013e318160864f
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.